Search

Your search keyword '"van Oijen, Martijn G. H."' showing total 522 results
Start Over Author "van Oijen, Martijn G. H."
522 results on '"van Oijen, Martijn G. H."'

3. Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma

Author

Belkouz, Ali, Van Roessel, Stijn, Strijker, Marin, van Dam, Jacob L., Daamen, Lois, van der Geest, Lydia G., Balduzzi, Alberto, Cacciaguerra, Andrea Benedetti, van Dieren, Susan, Molenaar, Quintus, Groot Koerkamp, Bas, Verheij, Joanne, Van Eycken, Elizabeth, Malleo, Giuseppe, Hilal, Mohammed Abu, van Oijen, Martijn G. H., Borbath, Ivan, Verslype, Chris, Punt, Cornelis J. A., Besselink, Marc G., and Klümpen, Heinz-Josef

Published
2022
Full Text
View/download PDF

4. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., van Berge Henegouwen, Mark I., Baas, Peter C., Bahadoer, Renu R., Belt, Eric J. T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J., van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P. R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E. N., Pierik, E. G. J. M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A. M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B. A. C., Stoop, Fanny J., Voeten, Daan M., Vugts, Guusje, Vijgen, Guy H. E. J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G. H., and Gisbertz, Suzanne S.

Published
2023
Full Text
View/download PDF

5. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Author

ten Hoorn, Sanne, Waasdorp, Cynthia, van Oijen, Martijn G. H., Damhofer, Helene, Trinh, Anne, Zhao, Lan, Smits, Lisanne J. H., Bootsma, Sanne, van Pelt, Gabi W., Mesker, Wilma E., Mol, Linda, Goey, Kaitlyn K. H., Koopman, Miriam, Medema, Jan Paul, Tuynman, Jurriaan B., Zlobec, Inti, Punt, Cornelis J. A., Vermeulen, Louis, and Bijlsma, Maarten F.

Published
2022
Full Text
View/download PDF

9. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care: The Dutch Nationwide Ivory Study

Author

Kalff, Marianne C., Henegouwen, Mark I. van Berge, Baas, Peter C., Bahadoer, Renu R., Belt, Eric J. T., Brattinga, Baukje, Claassen, Linda, Ćosović, Admira, Crull, David, Daams, Freek, van Dalsen, Annette D., Dekker, Jan Willem T., van Det, Marc J., Drost, Manon, van Duijvendijk, Peter, Eshuis, Wietse J., van Esser, Stijn, Gaspersz, Marcia P., Görgec, Burak, Groenendijk, Richard P. R., Hartgrink, Henk H., van der Harst, Erwin, Haveman, Jan Willem, Heisterkamp, Joos, van Hillegersberg, Richard, Kelder, Wendy, Kingma, B. Feike, Koemans, Willem J., Kouwenhoven, Ewout A., Lagarde, Sjoerd M., Lecot, Frederik, van der Linden, Philip P., Luyer, Misha D. P., Nieuwenhuijzen, Grard A. P., Olthof, Pim B., van der Peet, Donald L., Pierie, Jean-Pierre E. N., Pierik, E. G. J. M. Robert, Plat, Victor D., Polat, Fatih, Rosman, Camiel, Ruurda, Jelle P., van Sandick, Johanna W., Scheer, Rene, Slootmans, Cettela A. M., Sosef, Meindert N., Sosef, Odin V., de Steur, Wobbe O., Stockmann, Hein B. A. C., Stoop, Fanny J., Voeten, Daan M., Vugts, Guusje, Vijgen, Guy H. E. J., Weeda, Víola B., Wiezer, Marinus J., van Oijen, Martijn G. H., and Gisbertz, Suzanne S.

Published
2021
Full Text
View/download PDF

13. Origin and outcome of metastatic tumours to the testes: a nationwide study.

Author

Woortman, Carmen, van Leenders, Geert J. L. H., Hugen, Niek, van Oijen, Martijn G. H., and Nagtegaal, Iris D.

Subjects
PROPORTIONAL hazards models, TESTIS tumors, TESTIS, OVERALL survival, TUMORS, METASTASIS
Abstract

Objectives: To perform a retrospective cohort analysis for metastatic tumours in the testes to explore the timing, presentation and prognosis of this particular type of metastases and the factors that influence outcome. Patients and methods: A nationwide retrospective review of pathology reports of patients with pathologically confirmed metastases to the testis between 1991 and 2021 was performed. Data were collected from the Dutch nationwide pathology databank (PALGA) and the Netherlands Cancer Registry. Log‐rank testing and Kaplan–Meier analyses were used to assess overall survival (OS), and Cox proportional hazard models were used for multivariate survival analysis. Results: A total of 175 patients with a testicular metastasis were included. The median (range) age at diagnosis of testicular metastasis was 67 (3–88) years. Testicular metastases originated from a variety of primary tumours, although most frequently from the prostate (40.6%), kidney (13.7%), colon (10.3%), bladder (7.4%) and skin (5.7%). Synchronous testicular metastasis was detected in 53 cases, while 114 metachronous lesions were found after a median (interquartile range) interval of 22 (1–53) months after the original cancer diagnosis. OS after the diagnosis of a testicular metastasis was poor, with a median survival of 14.2 months (95% confidence interval 10.2–18.3). Primary tumour origin was an independent factor for survival, with worst survival for patients with primary skin, bladder and colon cancer. Conclusion: Testicular metastases are very uncommon and arise mainly from primary tumours anatomically close to the testes. Most patients develop metachronous testicular metastasis at an oligometastatic disease stage. These metastases are invariably associated with poor survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient preference non-randomized trial.

Author

Augustinus, Simone, Broekman, Thijmen, Creemers, Geert-Jan, Daamen, Lois A., van Dieren, Susan, de Groot, Jan-Willem B., Cirkel, Geert A., Homs, Marjolein Y. V., van Laarhoven, Hanneke W. M., van Leeuwen, Lobke, Los, Maartje, Luelmo, Saskia A. C., van Oijen, Martijn G. H., Spierings, Leontine E. A. M., de Vos-Geelen, Judith, Besselink, Marc G., and Wilmink, Johanna W.

Subjects
PANCREATIC tumors, RESEARCH, METASTASIS, MANN Whitney U Test, REGRESSION analysis, T-test (Statistics), QUESTIONNAIRES, CHI-squared test, DESCRIPTIVE statistics, KAPLAN-Meier estimator, QUALITY of life, LONGITUDINAL method, OVERALL survival, PROPORTIONAL hazards models
Abstract

The article focuses on a multicenter prospective patient preference trial named "Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN)." Topics include the lack of evidence on treatment initiation timing, the potential benefits and risks of immediate versus delayed systemic treatment, and the trial's methodology, including patient eligibility criteria and study design alteration due to recruitment challenges.

Published
2023
Full Text
View/download PDF

19. The association between wearable device metrics and clinical outcomes in oncology: A systematic review with evidence synthesis and meta-analysis

Author

Kos, Milan, Brouwer, Calvin G., van Laarhoven, Hanneke W. M., Hopman, Maria T. E., van Oijen, Martijn G. H., and Buffart, Laurien M.

Subjects
Hospitalization, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, Oncology, Survival, Circadian rhythm, Physical activity, Cancer treatment, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Metabolic Disorders Radboud Institute for Health Sciences [Radboudumc 6], Hematology, Wearable devices
Abstract

Contains fulltext : 292354.pdf (Publisher’s version ) (Open Access) BACKGROUND: The emerging study of wearable devices (WDs) in patients with cancer provides opportunities to harness real-time patient data for predicting clinical outcomes. We conducted a systematic review with best evidence synthesis to examine the association between WD metrics and clinical outcomes in patients with cancer. METHODS: MEDLINE and Embase were searched from inception until June 2022. Risk of bias assessment and best evidence synthesis were performed and, If possible, meta-analysis was conducted. RESULTS: A total of 34 studies was included. We found moderate-to-strong evidence for associations between circadian rest-activity metrics and OS. Disrupted I

Published
2023

20. Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers

Author

Belkouz, Ali, de Savornin Lohman, Elise, Thumma, Jyothi R., Groot Koerkamp, Bas, de Reuver, Philip R., van Oijen, Martijn G. H., Punt, Cornelis J. A., Nathan, Hari, Klümpen, Heinz-Josef, Internal medicine, and Surgery

Subjects
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Oncology, Geriatrics and Gerontology
Abstract

INTRODUCTION: The optimal treatment for unresected nonmetastatic biliary tract cancer (uBTC) is not well-established. The objective of this study was to analyze the treatment patterns and compare the differences in overall survival (OS) between different treatment strategies amongst older adults with uBTC.MATERIALS AND METHODS: We identified patients aged ≥65 years with uBTC using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2004-2015). Treatments were classified into chemotherapy, chemoradiotherapy, and radiotherapy. The primary outcome was OS. The differences in OS were analyzed using Kaplan-Meier curves and multivariable Cox proportional hazard regression.RESULTS: A total of 4352 patients with uBTC were included. The median age was 80 years and median OS was 4.1 months. Most patients (67.3%, n = 2931) received no treatment, 19.1% chemotherapy (n = 833), 8.1% chemoradiotherapy (n = 354), and 5.4% radiotherapy alone (n = 234). Patients receiving no treatment were older and had more comorbidities. Chemotherapy was associated with significantly longer OS than no treatment in uBTC (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.79-0.95), but no difference was found in the subgroups of intrahepatic cholangiocarcinoma (iCCA; HR 0.87, 95% CI 0.75-1.00) and gallbladder carcinoma (GBC; HR 1.09, 95% CI 0.86-1.39). In the sensitivity analyses, capecitabine-based chemoradiotherapy showed significantly longer OS in uBTC compared to chemotherapy (adjusted HR 0.71, 95% CI 0.53-0.95).DISCUSSION: A minority of older patients with uBTC receive systemic treatments. Chemotherapy was associated with longer OS compared to no treatment in uBTC, but not in the subgroups of iCCA and GBC. The efficacy of chemoradiotherapy, especially in perihilar cholangiocarcinoma using capecitabine-based chemoradiotherapy, may be further evaluated in prospective clinical trials.

Published
2023

27. Additional file 1 of Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Author

ten Hoorn, Sanne, Waasdorp, Cynthia, van Oijen, Martijn G. H., Damhofer, Helene, Trinh, Anne, Zhao, Lan, Smits, Lisanne J. H., Bootsma, Sanne, van Pelt, Gabi W., Mesker, Wilma E., Mol, Linda, Goey, Kaitlyn K. H., Koopman, Miriam, Medema, Jan Paul, Tuynman, Jurriaan B., Zlobec, Inti, Punt, Cornelis J. A., Vermeulen, Louis, and Bijlsma, Maarten F.

Abstract

Additional file 1: Supplementary Table S1. Expression dataset used for analysis. Supplementary Table S2. Prognostic value of ADAM12. Supplementary Table S3. Association of ADAM12 groups with survival, treatment and KRAS and BRAF mutation status. Supplementary Table S4. Prognostic value of ADAM12, stratified by primary tumor location. Supplementary Table S5. Characteristics pilot rectal cancer (n = 20). Supplementary Figure S1. ADAM12 expression correlates with activated stroma signature. Supplementary Figure S2. Multivariate analysis of relevant parameters and overall survival. Supplementary Figure S3. High serum ADAM12 levels associate with unfavorable outcome independent of treatment status. Supplementary Figure S4. Association between ADAM12 serum concentration and percentage tumor epithelium. Supplementary Figure S5. High serum ADAM12 levels associate with unfavorable outcome in mesenchymal tumours.

Published
2022
Full Text
View/download PDF

28. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.

Author

Spanjaart, Anne M., Pennings, Elise R. A., Kos, Milan, Mutsaers, Pim G. N. J., Lugtenburg, Pieternella J., van Meerten, Tom, van Doesum, Jaap A., Minnema, Monique C., Jak, Margot, van Dorp, Suzanne, Vermaat, Joost S. P., van der Poel, Marjolein W. M., van Oijen, Martijn G. H., Kuipers, Maria T., Nijhof, Inger S., and José Kersten, Marie

Subjects
SERVICES for caregivers, MEDICAL information storage & retrieval systems, SYSTEMATIC reviews, CELL receptors, HEALTH outcome assessment, DESCRIPTIVE statistics, RESEARCH funding, TUMORS, T cells, MEDLINE, EARLY diagnosis, ACUTE diseases, DRUG toxicity
Abstract

PURPOSE Prompt recognition of acute chimeric antigen receptor T (CAR T)-cell–mediated toxicities is crucial because adequate and timely management can prevent or reverse potential life-threatening complications. In the outpatient setting, patients and informal caregivers have to recognize and report signs and symptoms marking these acute toxicities. This study provides a core set of patient- and caregiver-reported signs and symptoms (outcomes, P/CROs) and definitions of red flags warranting immediate action to include in a daily checklist for support at home, with the goal to make outpatient post–CAR T-cell care safer, optimize patient and caregiver support, and thereby facilitating an early discharge/hospital visit reduction strategy. METHODS We performed a systematic review of phase II/III trials of US Food and Drug Administration–approved CAR T-cell products and selected all common and severe adverse events that could be translated into a P/CRO for inclusion in a two-round modified Delphi procedure. Eleven CAR T-cell–dedicated hematologists from the Dutch CAR T-cell tumorboard representing all treating centers selected P/CROs for inclusion in the core set and defined red flags. The final core set was evaluated with patients and caregivers. RESULTS From nine clinical trials, 457 adverse events were identified of which 42 could be used as P/CRO. The final core set contains 28 items, including five signs for measurement via wearables and two signs for caregiver-performed assessments. CONCLUSION This study provides a core set of P/CROs that can serve as a framework for (eHealth) tools that aim to enable patients and caregivers to more effectively recognize and report signs and symptoms of acute toxicities after CAR T-cell therapy, which will enhance safe outpatient treatment monitoring. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Keeping track of all ongoing colorectal cancer trials using a mobile application: Usability and satisfaction results of the Dutch Colorectal Cancer Group Trials application

Author

Huiskens, Joost, Gałek-Aldridge, Michael S., Bakker, Jean-Michel, Olthof, Pim B., van Gulik, Thomas M., Punt, Cornelis J. A., and van Oijen, Martijn G. H.

Subjects
clinical trials, Original Article, colorectal cancer, smartphone application
Abstract

Background and Aim: Both the number and complexity of medical trials are increasing vastly. To facilitate easy access to concise trial information, a freely available mobile application including all ongoing clinical trials of the Dutch Colorectal Cancer Group (DCCG) was developed. The aim of this study was to investigate the use and user satisfaction over the first 2 years. Methods: The application was launched in January 2015 on iOS and Android platforms. Google Analytics was used to monitor anonymous user data up to February 2017. In addition, an online survey regarding the use and satisfaction among health-care professionals and research affiliates active in the field of colorectal cancer in the Netherlands was conducted. Results: A total of 6173 unique users were identified, of which 1822 (30%) were from the Netherlands, representing a total of 16,065 and 10,987 (68%) sessions, respectively. The median session duration per day was 01:47 min (IQR 0:51–03:03). The mobile application was mostly used on Monday, Tuesday, and Thursday, and the number of sessions was highest during the following time frames: 12–13 pm (9%), 17–18 pm (9%), and 13–14 pm (8%). Of 121 survey responses, most were medical doctors (47%), nurses (25%), or researchers (9%), working either in a teaching (40%), academic hospital (32%), or general hospital (19%). 83% of all respondents rated the application 4 or higher for satisfaction on a 5-point scale. Highest reported reasons of the use were urgent trial inquiry (57%) and usage during multi-disciplinary meetings (49%). Conclusion: The DCCG Trials application is frequently used, and the majority of users is highly satisfied. Relevance for Patients: Clustering trial information into one platform, such as DCCG trials app, has shown to be useful for medical professionals treating patients with colorectal carcinoma in the Netherlands.

Published
2018

39. Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity

Author

Keikes, Lotte, primary, Kos, Milan, additional, Verbeek, Xander A A M, additional, Van Vegchel, Thijs, additional, Nagtegaal, Iris D, additional, Lahaye, Max J, additional, Méndez Romero, Alejandra, additional, De Bruijn, Sandra, additional, Verheul, Henk M W, additional, Rütten, Heidi, additional, Punt, Cornelis J A, additional, Tanis, Pieter J, additional, and Van Oijen, Martijn G H, additional

Published
2021
Full Text
View/download PDF

40. Linked Colour imaging for the detection of polyps in patients with Lynch syndrome: a multicentre, parallel randomised controlled trial

Author

Houwen, Britt B S L, primary, Hazewinkel, Yark, additional, Pellisé, María, additional, Rivero-Sánchez, Liseth, additional, Balaguer, Francesc, additional, Bisschops, Raf, additional, Tejpar, Sabine, additional, Repici, Alessandro, additional, Ramsoekh, D, additional, Jacobs, Maarten A J M, additional, Schreuder, Ramon-Michel M, additional, Kaminski, Michal Filip, additional, Rupinska, Maria, additional, Bhandari, Pradeep, additional, van Oijen, Martijn G H, additional, Koens, Lianne, additional, Bastiaansen, Barbara A J, additional, Tytgat, Kristien M, additional, Fockens, Paul, additional, Vleugels, Jasper L A, additional, and Dekker, E, additional

Published
2021
Full Text
View/download PDF

43. Serological markers predict inflammatory bowel disease years before the diagnosis

Author

van Schaik, Fiona D M, Oldenburg, Bas, Hart, Andrew R, Siersema, Peter D, Lindgren, Stefan, Grip, Olof, Teucher, Birgit, Kaaks, Rudolf, Bergmann, Manuela M, Boeing, Heiner, Carbonnel, Franck, Jantchou, Prevost, Boutron-Ruault, Marie-Christine, Tjønneland, Anne, Olsen, Anja, Crowe, Francesca L, Peeters, Petra H M, van Oijen, Martijn G H, and Bueno-de-Mesquita, H Bas

Published
2013
Full Text
View/download PDF

45. Linked Colour imaging for the detection of polyps in patients with Lynch syndrome: a multicentre, parallel randomised controlled trial.

Author

Houwen, Britt B. S. L., Hazewinkel, Yark, Pellisé, María, Rivero-Sánchez, Liseth, Balaguer, Francesc, Bisschops, Raf, Tejpar, Sabine, Repici, Alessandro, Ramsoekh, D., Jacobs, Maarten A. J. M., Schreuder, Ramon-Michel M., Kaminski, Michal Filip, Rupinska, Maria, Bhandari, Pradeep, van Oijen, Martijn G. H., Koens, Lianne, Bastiaansen, Barbara A. J., Tytgat, Kristien M., Fockens, Paul, and Vleugels, Jasper L. A.

Subjects
HEREDITARY nonpolyposis colorectal cancer, COLON polyps, FECAL occult blood tests, BOWEL preparation (Procedure), POLYPS
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results